Global Biobetters Market is segmented By Drug Class (Erythropoietin Biobetters, Insulin Biobetters, G-CSF Bioreactors, Monoclonal Antibodies Biobetters, Anti-Hemophilic Factor, Other), By Application (Cancer, Diabetes, Renal Disease, Neurodegenerative Disease, Genetic Disorders, Others), By Route of Administration (Oral, Subcutaneous, Inhaled, Intravenous, Others), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Other), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Biobetters Market Overview
The Global Biobetters Market size reached USD 45,336.0 million in 2022 and is projected to witness lucrative growth by reaching up to USD 85,917.0 million by 2030. The market is exhibiting a CAGR of 8.5% during the forecast period (2023-2030). The global biobetters market is anticipated to rise throughout the forecast period due to increased product approvals and launches.
The global biobetters market industry is driven by factors such as longer product half-life, lower likelihood of aggregation, greater efficacy, and purity, fewer adverse events, and easier & less costly manufacturing.
For instance, Neulasta is a biobetter of Amgen used to reduce the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. It is a long-acting form of G-CSF that stimulates the growth of white blood cells in the body and helps prevent infections after chemotherapy treatments.
Biobetters Market Scope
|
Metrics |
Details |
|
CAGR |
8.5% |
|
Size Available for Years |
2021-2030 |
|
Forecast Period |
2023-2030 |
|
Data Availability |
Value (USD ) |
|
Segments Covered |
Drug Class, Application, Route of Administration, Distribution channel, and Region |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
|
Fastest Growing Region |
Asia-Pacific |
|
Largest Region |
North America |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more insights - Download the Sample
Biobetters Market Dynamics
The Advantage of Lower Adverse Effects is Driving the Growth of the Market
Biobetters are the biotechnological advancement for the treatment of many diseases. The biobetters have lower adverse effects which constantly driving the market growth. Biobetters also have many driving factors like longer product half-life, greater efficacy, and so on. For instance, MedImmune, AstraZeneca's biologics arm, launched a biobetters effort to improve efficacy, and safety by lowering side effects, and convenience.
A biobetter can be assigned a premium price due to its improved characteristics, but cost savings can be achieved due to reduced dosages. This affects payers' willingness to purchase the product. For instance, Neulasta has a higher commercial value than Neupogen, with U.S. sales of D 3.8 billion in 2014, reflecting the commercial value of a biobetter.
Growing Demand for Pegylation
Pegylation (i.e., the addition of PEG) is being used to create long-acting versions of successful biologics, such as Amgen's Neulasta, and to make biobetters of their own drugs or those of other innovators. For instance, Roche created mircera, a pegylated biobetter of Amgen's Epogen, which was approved by the FDA for once-monthly dosing to anemic patients.
Increasing Biosimilar Competition will Hamper the Market Growth
Increasing biosimilar competition for the biobetters is expected to restrain the market growth during the forecast period. Advancements in the development of biosimilars is decreasing the demand for biobetter market growth.
Biobetters Market Segment Analysis
The global biobetters market is segmented by drug class, by application and by route of administration.
Bispecific Antibodies Biobetters Segment is Expected to Dominate the Biobetters Market
Bispecific antibodies biobetters segment is expected to dominate the biobetters capturing a market share of around 36.1%. The advanced healthcare infrastructure coupled with rapid advancements in technology is expected to play an imperative role in boosting the growth of the biobetters market in the forecast period.
Bispecific antibodies (BsAbs) consist of two binding sites directed at two antigens or two epitopes of the same antigen. The primary application of BsAbs has been to shift cytotoxic immune effector cells for the enhanced killing of tumor cells by Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and other cytotoxic mechanisms carried out by the effector cells.
Source: DataM Intelligence Analysis (2023)
Biobetters Market Geographical Share
North America Region Holds the Largest Market Share of Around 39.4% in Global Biobetters Market
North American region dominates the global biobetters market. The United States holds over half of the world's R&D in pharmaceuticals and most new medicines, with USD 75 billion in R&D and IP rights.
Source: DataM Intelligence Analysis (2023)
Biobetters Market Companies
The major global players include Amgen Inc., Merck KGaA., Mabpharm Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Celltrion Healthcare, Novo Nordisk A/S, Biogen, Aequilibrium Pharma, Pfizer and others.
COVID-19 Impact on Biobetters Market
Russia-Ukraine Conflict Analysis
Russia and Ukraine war significantly impacted the global biobetters market growth. The situation in Ukraine will have a variety of effects on performing clinical trials, but it mainly affects the closure of treatment facilities, internal displacement, and forced migration. The war is expected to have an effect on the contribution of Russian clinical trial sites, which will have an overall negative impact throughout the world.
Key Developments
- In January 2023, Celltrion Healthcare, a world's leading company that specializes in biologics by offering high-quality biosimilars, announced its submission of a biologics license application (BLA) for Remsima SC, a biobetter of the company’s infliximab biosimilar (Remsima) that allows for subcutaneous administration.
- In February 2023, ST Pharma, a subsidiary of Dong-A Socio Group, signed an agreement with Multiverse Pharma for joint research on AER platform technology and biobetter mRNA drugs.
- In March 2023, Celltrion Healthcare presented positive Phase III safety and efficacy data for its Remsima SC biobetter, infliximab biobetter, as maintenance therapy in patients with IBD.
Why Purchase the Report?
- To visualize the global biobetters market segmentation based on drug class, application, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of global biobetters market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global Biobetters market report would provide approximately 54 tables, 46 figures, and 195 Pages.
